Stocks and Investing Stocks and Investing
Tue, January 4, 2022
Mon, January 3, 2022

Aaron Gal Maintained (ABBV) at Buy with Increased Target to $155 on, Jan 3rd, 2022


Published on 2024-10-27 19:06:57 - WOPRAI, Aaron Gal
  Print publication without navigation


Aaron Gal of Bernstein, Maintained "AbbVie Inc." (ABBV) at Buy with Increased Target from $130 to $155 on, Jan 3rd, 2022.

Aaron has made no other calls on ABBV in the last 4 months.



There are 9 other peers that have a rating on ABBV. Out of the 9 peers that are also analyzing ABBV, 3 agree with Aaron's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Chris Shibutani of "Goldman Sachs" Initiated at Hold and Held Target at $113 on, Friday, December 17th, 2021
  • Luisa Hector of "Berenberg" Maintained at Hold and Held Target at $105 on, Wednesday, November 24th, 2021
  • Carter Gould of "Barclays" Maintained at Hold with Increased Target to $118 on, Monday, November 1st, 2021


These are the ratings of the 6 analyists that currently disagree with Aaron


  • Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $165 on, Thursday, December 9th, 2021
  • Navin Jacob of "UBS" Maintained at Strong Buy with Increased Target to $129 on, Monday, November 29th, 2021
  • Justin Smith of "Societe Generale" Upgraded from Hold to Strong Buy and Held Target at $172 on, Tuesday, November 23rd, 2021
  • Geoffrey Porges of "SVB Leerink" Maintained at Buy with Decreased Target to $135 on, Monday, November 1st, 2021
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $124 on, Monday, November 1st, 2021
  • Vamil Divan of "Mizuho" Maintained at Strong Buy with Increased Target to $132 on, Monday, November 1st, 2021
Contributing Sources